FBXL20

Across TCGA pan-cancer cohorts, FBXL20 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of FBXL20’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where FBXL20 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FBXL20 is over-expressed in tumor, although a few such as LSCC and COAD show the opposite, repressed pattern.

PDAC, LSCC, and COAD are the cancer types where FBXL20 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FBXL20 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	All	+0.454	<.001	9	view →
LSCC	Female	All	−0.310	<.001	8	view →
COAD	Female	All	−0.290	<.001	6	view →
CCRCC	Male	All	−0.196	<.001	6	view →
HNSC	Male	II,III,IV	+0.191	.001	6	view →
OV	All	All	−0.317	.019	2	view →
LUAD	Male	III,IV	−0.128	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

FBXL20–PDAC

Open the PDAC breakdown →